Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors

BACKGROUND: Although immune checkpoint inhibitors (ICIs) generally show poor therapeutic efficacy in patients with epidermal growth factor receptor (EGFR) mutations, certain research indicate that a small proportion of these patients do respond to ICIs. The present study sought to identify the featu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qian, Shang, Xiaoling, Liu, Ni, Ma, Xinchun, Han, Wenfei, Wang, Xiuwen, Liu, Yanguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388930/
https://www.ncbi.nlm.nih.gov/pubmed/35990690
http://dx.doi.org/10.3389/fimmu.2022.931718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388930/
https://www.ncbi.nlm.nih.gov/pubmed/35990690
http://dx.doi.org/10.3389/fimmu.2022.931718

Ejemplares similares